Analysts Are Bullish on These Healthcare Stocks: Beyond Air (XAIR), Diamedica Therapeutics (DMAC)We anticipate the differentiated aspects of the second generation LungFit PH device (e.g., its smaller footprint and air-transport compatibility) to drive adoption after FY27. Consequently, while we are reducing our 12-month price target based on reduced near-term revenue estimates, we continue to believe that the market is underappreciating the potential of LungFit PH and are encouraged that the company expects that its cash will be sufficient to fund operations into calendar 2027.